Paper37313232
Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.
Berman C and 2 others. touchREV Endocrinol, 2023. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth. Papers, record 37313232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37313232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References78
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20519125 | GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. | Cell Metab | 2010 | https://conductscience.org/library/papers/20519125 | PubMed |
| 2 | 24836562 | The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. | Cell Metab | 2014 | https://conductscience.org/library/papers/24836562 | PubMed |
| 3 | 29617641 | Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. | Cell Metab | 2018 | https://conductscience.org/library/papers/29617641 | PubMed |
| 4 | 27486237 | Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities. | Diabetes Care | 2016 | https://conductscience.org/library/papers/27486237 | PubMed |
| 5 | 34964141 | Clinical review of subcutaneous semaglutide for obesity. | J Clin Pharm Ther | 2022 | https://conductscience.org/library/papers/34964141 | PubMed |
| 6 | 29941499 | Can We RISE to the Challenge of Youth-Onset Type 2 Diabetes? | Diabetes Care | 2018 | https://conductscience.org/library/papers/29941499 | PubMed |
| 7 | 34018306 | Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives. | Pediatr Diabetes | 2021 | https://conductscience.org/library/papers/34018306 | PubMed |
| 8 | 25036533 | Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. | Diabetes Technol Ther | 2014 | https://conductscience.org/library/papers/25036533 | PubMed |
| 9 | 31859529 | Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model. | Diabetes Technol Ther | 2020 | https://conductscience.org/library/papers/31859529 | PubMed |
| 10 | 35679098 | Once-Weekly Exenatide in Youth With Type 2 Diabetes. | Diabetes Care | 2022 | https://conductscience.org/library/papers/35679098 | PubMed |
| 11 | 9892226 | Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. | Diabetes | 1999 | https://conductscience.org/library/papers/9892226 | PubMed |
| 12 | 33435250 | Current Perspectives on Management of Type 2 Diabetes in Youth. | Children (Basel) | 2021 | https://conductscience.org/library/papers/33435250 | PubMed |
| 13 | 19776173 | Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. | Am J Physiol Renal Physiol | 2009 | https://conductscience.org/library/papers/19776173 | PubMed |
| 14 | 27732328 | Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. | J Clin Endocrinol Metab | 2017 | https://conductscience.org/library/papers/27732328 | PubMed |
| 15 | 11095432 | Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. | J Clin Endocrinol Metab | 2000 | https://conductscience.org/library/papers/11095432 | PubMed |
| 16 | 18201212 | Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. | Diabet Med | 2008 | https://conductscience.org/library/papers/18201212 | PubMed |
| 17 | 36044100 | GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? | Curr Atheroscler Rep | 2022 | https://conductscience.org/library/papers/36044100 | PubMed |
| 18 | 33068776 | GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. | Mol Metab | 2021 | https://conductscience.org/library/papers/33068776 | PubMed |
| 19 | 22369102 | Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. | Pediatr Diabetes | 2012 | https://conductscience.org/library/papers/22369102 | PubMed |
| 20 | 26394161 | Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. | J Hepatol | 2016 | https://conductscience.org/library/papers/26394161 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41798193 | Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/41798193 | PubMed |
| 41300545 | Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. | Children (Basel) | 2025 | https://conductscience.org/library/papers/41300545 | PubMed |
| 41169459 | Young patients with type 2 diabetes have high relative risks for complications in a country with middle-high sociodemographic index, similarly to those countries with high index. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41169459 | PubMed |
| 40890660 | Critical discourse analysis of social media advertisements for GLP-1 receptor agonist weight loss drugs: implications for public perceptions and health communication. | BMC Public Health | 2025 | https://conductscience.org/library/papers/40890660 | PubMed |
| 40260650 | Effects of GLP-1 Receptor Agonists on Paediatric Population in a Real World Setting. | Endocrinol Diabetes Metab | 2025 | https://conductscience.org/library/papers/40260650 | PubMed |
| 39683477 | Current Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review. | Nutrients | 2024 | https://conductscience.org/library/papers/39683477 | PubMed |
| 39672599 | Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement. | J Clin Endocrinol Metab | 2025 | https://conductscience.org/library/papers/39672599 | PubMed |
| 39493561 | Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum. | World J Diabetes | 2024 | https://conductscience.org/library/papers/39493561 | PubMed |
| 38539310 | Glucagon-like Peptide-1 Receptor Agonists-A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD). | Children (Basel) | 2024 | https://conductscience.org/library/papers/38539310 | PubMed |
| 38173379 | Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study". | Ann Pediatr Endocrinol Metab | 2023 | https://conductscience.org/library/papers/38173379 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37313232
GET https://conductscience.org/api/papers/v1/37313232/references?page=2